DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-527/S-005

Boehringer Ingelheim Pharmaceuticals Inc.
900 Ridgebury Rd/P.O. Box 368
Ridgefield, CT 06877-0368

Attention: Kelly S. Billingham
Manager, Product Labeling
Drug Regulatory Affairs

Dear Ms. Billingham:

Please refer to your supplemental new drug application dated March 8, 2006, received March 9, 2006, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Atrovent HFA (ipratropium bromide HFA) Inhalation Aerosol.

This "Changes Being Effected" supplemental new drug application provides for the addition of 'pruritis' to the ADVERSE REACTIONS section of the package insert.

We completed our review of this supplemental new drug application. It is approved, effective on the date of this letter, for use as recommended in the final printed labeling (FPL) submitted on March 8, 2006 (copy of approved text enclosed).

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
WO 22, Room 4447
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Lori Garcia, Regulatory Project Manager, at (301) 796-1212.

Sincerely,

{See appended electronic signature page}

Badrul A. Chowdhury, M.D., Ph.D.
Director
Division of Pulmonary and Allergy Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Badrul Chowdhury
9/5/2006 06:11:17 PM